Abstract: The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. wherein R represents the ring A or 2-pyridinyl or 2-pyridinyl-N-oxide; R1 is selected from halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl, and S(O)nC1-4alkyl groups; R2 and R3, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl and cyano groups; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.

Abstract: A system and method of the present invention controls the Brix of a concentrated juice product. The results of a process change in disturbance variables on the vapor temperature in at least one of the effects of the multi-stage, multi-effect evaporator are predicted and the Brix of the concentrated juice product discharged from the evaporator is controlled based on the predicted results by controlling one of steam or juice fed into the evaporator.

Abstract: A system and method of the present invention controls the Brix of a concentrated juice product. The results of a process change in disturbance variables on the vapor temperature in at least one of the effects of the multi-stage, multi-effect evaporator are predicted and the Brix of the concentrated juice product discharged from the evaporator is controlled based on the predicted results by controlling one of steam or juice fed into the evaporator.